Pacira Biosciences Inc Revenue Growth Rates (PCRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Pacira Biosciences inc   (NASDAQ: PCRX)
 

PCRX's Revenue Growth by Quarter and Year

Pacira Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PCRX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 192.40
1st Quarter March 177.38
FY 369.78

PCRXs Annual Revenue
Pacira Biosciences Inc 's Revenue in the fiscal year 2025 $ 726.41 millions
Pacira Biosciences Inc 's Revenue in the fiscal year 2024 $ 700.97 millions
Pacira Biosciences Inc 's Revenue in the fiscal year 2023 $ 674.98 millions
Pacira Biosciences Inc 's Revenue in the fiscal year 2022 $ 666.82 millions
Pacira Biosciences Inc 's Revenue in the fiscal year 2021 $ 541.53 millions




PCRX Revenue second quarter 2026 Y/Y Growth Comment
Pacira Biosciences inc reported Revenue growth of 6.24% year on year in the second quarter 2026, to $ 192.40 millions, this is lower than Pacira Biosciences Inc 's recent average Revenue rise of 43.96%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 114 other companies have achieved higher Revenue growth. While Pacira Biosciences Inc ' s Revenue increase of 6.24% ranks overall at the positon no. 2108 in the second quarter 2026.


PCRX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 5.14 % 3.32 % 5.4 %
3rd Quarter September - 6.5 % 2.83 % -2.11 %
2nd Quarter June 6.24 % 1.73 % 5.05 % 0.04 %
1st Quarter March 5.01 % 1.08 % 4.23 % 1.49 %
FY   - 3.63 % 3.85 % -

Financial Statements
Pacira Biosciences Inc 's second quarter 2026 Revenue $ 192.40 millions PCRX's Income Statement
Pacira Biosciences Inc 's second quarter 2025 Revenue $ 181.10 millions Quarterly PCRX's Income Statement


PCRX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 9.66 % 11.08 % 10.56 %
3rd Quarter September - -0.87 % -5.31 % -3.27 %
2nd Quarter June 8.47 % 7.21 % 6.52 % 5.69 %
1st Quarter March -9.9 % -9.79 % -7.79 % -6.76 %
FY (Year on Year)   - 3.63 % 3.85 % -


Back to PCRX Growth rate Comparisons >> Back to PCRX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #115
Healthcare Sector #313
Overall #2108

Revenue Y/Y Growth Statistics
High Average Low
488.93 % 43.96 % -64.93 %
(Mar 31 2015)   (Mar 31 2016)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #115
Healthcare Sector #313
Overall #2108
Revenue Y/Y Growth Statistics
High Average Low
488.93 % 43.96 % -64.93 %
(Mar 31 2015)   (Mar 31 2016)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Pacira Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
279.78 % 11.97 % -70.5 %
(Dec 31 2014)  


PCRX's II. Quarter Q/Q Revenue Comment
Pacira Biosciences inc achieved in the II. Quarter 2026 below company average Revenue increase of 8.47% quarter on quarter, to $ 192.40 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 7.21% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Pacira Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 875.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #136
Overall #875
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #136
Overall #875
Revenue Q/Q Growth Statistics
High Average Low
279.78 % 11.97 % -70.5 %
(Dec 31 2014)  


PCRX's II. Quarter Q/Q Revenue Comment
Pacira Biosciences inc achieved in the II. Quarter 2026 below company average Revenue increase of 8.47% quarter on quarter, to $ 192.40 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 7.21% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Pacira Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 875.


Pacira Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 746.16 $ 734.86 $ 726.41 $ 716.79 $ 705.85
Y / Y Revenue Growth (TTM) 5.71 % 4.57 % 3.63 % 3.14 % 2.25 %
Year on Year Revenue Growth Overall Ranking # 2335 # 1092 # 1630 # 1480 # 1220
Seqeuential Revenue Change (TTM) 1.54 % 1.16 % 1.34 % 1.55 % 0.44 %
Seq. Revenue Growth (TTM) Overall Ranking # 2528 # 1515 # 1389 # 1584 # 1358


Cumulative Revenue growth Comment
Although Pacira Biosciences Inc 's Annual Revenue growth year on year were below company's average 31.77% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 5.71% year on year, from 4.57% in Mar 31 2026.

In the Healthcare sector 337 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1092 to 2335.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 120
Healthcare Sector # 338
Overall # 2335

Revenue TTM Y/Y Growth Statistics
High Average Low
221.08 %
 31.77 %
-27.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 120
Sector # 369
S&P 500 # 2528
Cumulative Revenue growth Comment
Although Pacira Biosciences Inc 's Annual Revenue growth year on year were below company's average 31.77% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 5.71% year on year, from 4.57% in Mar 31 2026.

In the Healthcare sector 337 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1092 to 2335.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 120
Healthcare Sector # 338
Overall # 2335

Revenue TTM Y/Y Growth Statistics
High Average Low
221.08 %
31.77 %
-27.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 120
Sector # 369
S&P 500 # 2528




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PCRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Rapid Micro Biosystems Inc 10.91%$ 10.906 millions
Livanova Plc10.80%$ 10.797 millions
Cerus Corporation10.52%$ 10.517 millions
Interpace Biosciences Inc 10.33%$ 10.331 millions
Warby Parker Inc 10.25%$ 10.253 millions
Neuronetics Inc 10.25%$ 10.249 millions
Elanco Animal Health Incorporated10.23%$ 10.234 millions
Quest Diagnostics Inc10.21%$ 10.214 millions
Gilead Sciences Inc 10.18%$ 10.181 millions
Lifeloc Technologies Inc 10.16%$ 10.163 millions
Abbvie Inc 10.16%$ 10.160 millions
Concentra Group Holdings Parent Inc 10.03%$ 10.030 millions
Lemaitre Vascular Inc 10.02%$ 10.017 millions
Amneal Pharmaceuticals Inc 9.93%$ 9.934 millions
Merit Medical Systems Inc9.79%$ 9.792 millions
Idexx Laboratories Inc9.73%$ 9.728 millions
Lenz Therapeutics Inc 9.72%$ 9.720 millions
Encompass Health Corporation9.58%$ 9.584 millions
Trisalus Life Sciences Inc 9.57%$ 9.567 millions
Amgen Inc 9.53%$ 9.533 millions
Sotera Health Company9.45%$ 9.452 millions
Illumina Inc 9.44%$ 9.443 millions
Stryker Corp9.42%$ 9.415 millions
International Stem Cell Corporation9.32%$ 9.318 millions
Cytosorbents Corporation9.29%$ 9.292 millions
Resmed Inc 9.22%$ 9.222 millions
Fate Therapeutics Inc 9.18%$ 9.177 millions
Bausch and Lomb Corp9.08%$ 9.077 millions
Pacs Group Inc 9.07%$ 9.071 millions
Electromed Inc 8.97%$ 8.968 millions


About Pacira Biosciences Inc Revenue Growth Rates (PCRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Pacira Biosciences Inc (CIK 1396814).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-052635
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Pacira Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.